Core Insights - The report highlights the significant role of company secretaries (董秘) in connecting investors and listed companies, with a total salary of 4.086 billion yuan for A-share company secretaries in 2024, averaging 754,300 yuan per year [1] Salary Distribution - The salary distribution for company secretaries in the A-share biopharmaceutical sector shows that 32% earn below 500,000 yuan, 41% earn between 500,000 and 1 million yuan, 23% earn between 1 million and 2 million yuan, 3% earn between 2 million and 3 million yuan, and 1% earn above 3 million yuan [5] Age Distribution - The age distribution of company secretaries indicates that 47% are between 40-50 years old, 23% are over 50, 29% are between 30-40, and only 1% are under 30, with the youngest being 28 years old [1] Educational Background - The educational background of company secretaries shows that 4% have an associate degree, 42% hold a bachelor's degree, 50% have a master's degree, and 4% possess a doctoral degree, with over half holding a master's degree or higher [3] Investor Engagement - There is a significant variance in the number of investor meetings held by companies, with 32% of companies hosting fewer than 10 meetings per year, while only 1% have more than 1,000 meetings [9] Top Earning Company Secretaries - The top five highest-paid company secretaries have salaries ranging from 325.65 million yuan to 738.76 million yuan, with the youngest among them being 32 years old and having just started in the role [7]

专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 分行业来看，统计数据显示，A股共有494家上市医药生物公司，董事会秘书聘任总体情况如下（部分 统计口径剔除无效数据）。 从董秘的年龄分布来看，介于40-50岁的董秘是市场的中坚力量，占比达到47%；50岁以上的董秘占比 为23%；30-40岁的董秘群体占比为29%；近几年董秘群体中新生力量渐增，30岁以下的年轻董秘占比达 到1%，其中最年轻的上市公司董秘年仅28岁，为康乐卫士的任恩奇。 从接待投资者次数看，各上市公司接待情况差异较大。经统计，年接待次数小于10次的公司数量为129 家，占比32%；接待次数为10次-100次的公司数量为149家，占比37%；接待次数为100次-300次的公司 数量为79家，占比20%；接待次数为300次-1000次的公司数量为42家，占比10%；接待次数大于1000次 的公司数量为5家，占比1%。 ...

Core Insights - The report highlights that the total salary of A-share listed company secretaries reached 4.086 billion yuan in 2024, with an average annual salary of 754,300 yuan [1] - Over 21% of the secretaries earn more than 1 million yuan annually, indicating a significant compensation level in the industry [1] Salary Distribution - The salary distribution among secretaries in the biopharmaceutical sector shows that 32% earn below 500,000 yuan, 41% earn between 500,000 and 1 million yuan, 23% earn between 1 million and 2 million yuan, 3% earn between 2 million and 3 million yuan, and 1% earn above 3 million yuan [5] - Five secretaries with salaries exceeding 3 million yuan include Li Wenmei from Mindray Medical (7.3876 million yuan), Jiang Yueheng from Yifang Bio (5.2065 million yuan), and others, with the youngest being 32 years old [7] Age and Educational Background - The age distribution of secretaries shows that those aged 40-50 constitute 47%, while those over 50 account for 23%, and those aged 30-40 make up 29%. Secretaries under 30 represent 1% [1] - In terms of educational qualifications, 4% have an associate degree, 42% hold a bachelor's degree, 50% possess a master's degree, and 4% have a doctoral degree, with over half holding a master's degree or higher [3] Investor Engagement - There is a significant variance in the number of investor meetings held by companies, with 32% of companies hosting fewer than 10 meetings annually, while only 1% have more than 1,000 meetings [9] - The top five companies with the most investor meetings include Sanofi Biologics and others, with meeting counts ranging from 1,107 to 2,661 [10]

Core Viewpoint - The A-share market has seen a strong performance in the biopharmaceutical sector, particularly in vaccine stocks, driven by the release of the 2025 treatment plan for Chikungunya virus, highlighting the lack of available vaccines in China [1][2] Group 1: Market Performance - Shenyuan Biological (申联生物) rose by over 10%, with a year-to-date increase of 42.60% and a market capitalization of 3.203 billion [2] - Global Printing (环球印务) increased by 9.96%, with a market cap of 3.252 billion and a year-to-date rise of 34.04% [2] - Guanhao Biological (冠昊生物) saw a 7.70% increase, with a market cap of 4.969 billion and a year-to-date increase of 55.65% [2] - Sealy Medical (塞力医疗) rose by 5.60%, with a market cap of 6.055 billion and an impressive year-to-date increase of 339.06% [2] - Other notable performers include Kanglao Weishi (康乐卫士) up 4.98%, Jinhai Biological (金河生物) up 4.62%, and Weilan Biological (蔚蓝生物) up 4.41% [1][2] Group 2: Regulatory and Health Measures - The 2025 Chikungunya virus treatment plan emphasizes preventive measures such as eliminating mosquito breeding sites and using repellents [1] - Travelers to Chikungunya endemic areas are advised to enhance their preventive awareness to avoid infection [1] - Currently, there is no available vaccine for the Chikungunya virus in China, indicating a potential market opportunity for vaccine development [1]

Core Viewpoint - The A-share market has seen a strong performance in the biopharmaceutical sector, particularly in vaccine stocks, driven by the release of the 2025 treatment plan for Chikungunya virus, which has heightened awareness and demand for related medical solutions [1][2]. Group 1: Stock Performance - Shenyuan Biological (申联生物) rose by 10.33%, with a market capitalization of 3.203 billion [2] - Global Printing (环球印务) increased by 9.96%, with a market capitalization of 3.252 billion [2] - Guanhao Biological (冠昊生物) saw a rise of 7.70%, with a market capitalization of 4.969 billion [2] - Seer Medical (塞力医疗) grew by 5.60%, with a market capitalization of 6.055 billion [2] - Kanglao Guardian (康乐卫士) increased by 4.98%, with a market capitalization of 4.793 billion [2] - Jinhai Biological (金河生物) rose by 4.62%, with a market capitalization of 5.594 billion [2] - Weilan Biological (蔚蓝生物) increased by 4.41%, with a market capitalization of 3.831 billion [2] - Yongshun Biological (永顺生物) rose by 3.94%, with a market capitalization of 2.742 billion [2] - Dezhan Health (德展健康) increased by 3.51%, with a market capitalization of 10.5 billion [2] - Junzheng Group (君正集团) rose by 3.37%, with a market capitalization of 46.6 billion [2] - Kanghua Biological (康华生物) increased by 3.19%, with a market capitalization of 10.4 billion [2] Group 2: Market Context - The 2025 version of the Chikungunya virus treatment plan emphasizes preventive measures such as eliminating mosquito breeding grounds and using repellents [1] - There is currently no available vaccine for the Chikungunya virus in China, which may drive demand for vaccine development [1] - Free nucleic acid screening for Chikungunya virus is being conducted in Lecong Town, Shunde District, targeting close contacts of confirmed cases [1]

Core Insights - The report predicts that the North Exchange 50 Index will undergo component adjustments on September 11, 2025, with a review cutoff date of July 31, 2025 [3] - The predicted additions to the North Exchange 50 Index include Xingtu Measurement Control, Wanyuantong, Kanglwei, Lintai New Materials, and Juxing Technology, while Tianfangbiao, Huami New Materials, Haosheng Electronics, Chuangyuan Xinke, and Gebijia are expected to be removed [3][4] - Historical data indicates that, prior to adjustments, the average return of newly added stocks outperformed the index in 9 out of 11 instances, with an average excess return of 4.8%, while stocks being removed underperformed in 9 instances with an average excess return of -2.7% [3][8] Component Adjustments - The average daily trading volume and total market capitalization over the past six months were used to determine the adjustments, with specific metrics for each stock listed [3][4] - The predicted new components have varying average daily trading volumes, with Kanglwei at 632.9 million yuan and Lintai New Materials at 145.06 million yuan [4] - The report also lists potential candidates for inclusion, such as Yizhi Moyu, Wantong Hydraulic, Leishen Technology, and Wuhan Land Electric [3][4] Impact of Index Adjustments - The North Exchange 50 Index product size reached 11.162 billion yuan, accounting for 8.86% of the free float market capitalization, indicating a growing trend in index-based investments [3][11] - The report calculates the impact coefficients for the stocks being added and removed, with Kanglwei having the highest impact coefficient at 3.46, followed by Lintai New Materials at 2.17 [3][11] - The report emphasizes the importance of monitoring stocks with high impact coefficients as the adjustment date approaches [3]

证券代码：833575 证券简称：康乐卫士 公告编号：2025-083 近日，北京康乐卫士生物技术股份有限公司（以下简称"公司"）控股子公 司康乐卫士（昆明）生物技术有限公司（以下简称"昆明康乐"）收到云南省药 品监督管理局批准变更并换发的《药品生产许可证》，本次变更主要涉及生产范 围增加了重组九价人乳头瘤病毒（6/11/16/18/31/33/45/52/58 型）疫苗（大肠埃希 菌）（以下简称"九价 HPV 疫苗"）。现将有关情况公告如下： 一、《药品生产许可证》主要信息 企业名称：康乐卫士（昆明）生物技术有限公司 北京康乐卫士生物技术股份有限公司 社会信用代码：91530100MA6PJHNN5K 关于子公司药品生产许可证变更的公告 许可证编号：滇 20240254 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 分类码：As 注册地址：云南省滇中新区大板桥街道办事处长水社区临空产业园向贤路 508 号 发证机关：云南省药品监督管理局 有效期至：2029 年 8 月 1 日 生产地址和生产范围：云 ...

证券代码：833575 证券简称：康乐卫士 公告编号：2025-081 北京康乐卫士生物技术股份有限公司 关于对北京证券交易所 2024 年年报问询函的回复公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 北京康乐卫士生物技术股份有限公司（以下简称"公司"）于 2025 年 6 月 20 日收到北京证券交易所上市公司管理部下发的《关于对北京康乐卫士生物技术股 份有限公司的年报问询函》（年报问询函【2025】第 019 号，以下简称《问询函》）， 公司和安永华明会计师事务所（特殊普通合伙）（以下简称"年审会计师"）对 《问询函》认真进行了逐项落实，现就相关问题回复公告如下（如无特别说明， 本回复公告中的简称或名词的释义与公司《2024 年年度报告》中的相同）： 问题 1. 关于研发支出 2024 年度，你公司研发支出为 33,163.34 万元，同比下降 24.39%，其中， 资本化的研发支出 7,796.13 万元，同比下降 61.51%；费用化的研发支出为 25,367.22 万元，同比增加 7. ...

就北京证券交易所上市公司管理部 《关于对北京康乐卫士生物技术股份有限公司的年报问询函》第 1-7 项涉及财务报表项目 问询意见的专项说明 北京证券交易所上市公司管理部： 安永华明会计师事务所（特殊普通合伙）（以下简称"我们"）接受委托，审计了北京康 乐卫士生物技术股份有限公司（以下简称"康乐卫士"或"公司"）2024 年度按照企业会计 准则编制的财务报表，并于 2025 年 4 月 29 日出具了编号为安永华明（2025）审字第 70054764_A01 号的带强调事项段的无保留意见审计报告。 按照企业会计准则的规定编制财务报表是公司管理层的责任。我们对康乐卫士 2024 年 度的财务报表执行审计程序的目的，是对康乐卫士的财务报表是否在所有重大方面按照企业 会计准则的规定编制，是否公允反映了康乐卫士 2024 年 12 月 31 日的合并及公司财务状 况以及 2024 年度的合并及公司经营成果和现金流量表发表审计意见，不是对上述财务报表 中的个别项目的金额或个别附注单独发表意见。 根据北京证券交易所上市公司管理部（以下简称："贵部"）出具的《关于对北京康乐卫 士生物技术股份有限公司的年报问询函》（年报问询函【 ...

Core Points - As of July 3, the total margin financing and securities lending balance on the Beijing Stock Exchange reached 5.921 billion yuan, an increase of 18.9934 million yuan from the previous trading day, marking the ninth consecutive day of increase in financing balance [1] - The stocks with the highest financing balances include Jinbo Biological, Airong Software, and Better Ray, with financing balances of 356 million yuan, 170 million yuan, and 155 million yuan respectively [1] - A total of 135 stocks had net financing purchases on July 3, with 39 stocks having net purchases exceeding 1 million yuan, led by Jinbo Biological with a net purchase of 21.4285 million yuan [1][2] Industry Analysis - The industries with the highest concentration of stocks with net financing purchases exceeding 1 million yuan are machinery equipment, electronics, and computers, with 8, 5, and 4 stocks respectively [2] - On July 3, the average decline for stocks with net financing purchases over 1 million yuan was 0.04%, with notable gainers including Huayang Racing, Zhuozhao Point Glue, and Yuanhang Precision, which rose by 7.80%, 5.96%, and 3.55% respectively [2] - The average turnover rate for stocks with net financing purchases over 1 million yuan was 6.54%, with the highest turnover rates seen in Keli Co., Gaisi Food, and Knight Dairy, at 26.52%, 19.44%, and 17.87% respectively [2]